Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Variability of CYP2J2 expression in human fetal tissues.

Gaedigk A, Baker DW, Totah RA, Gaedigk R, Pearce RE, Vyhlidal CA, Zeldin DC, Leeder JS.

J Pharmacol Exp Ther. 2006 Nov;319(2):523-32. Epub 2006 Jul 25.

2.

Cytochrome P450 enzymes: central players in cardiovascular health and disease.

Elbekai RH, El-Kadi AO.

Pharmacol Ther. 2006 Nov;112(2):564-87. Epub 2006 Jul 7. Review.

PMID:
16824612
3.

Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms.

Lu T, Ye D, Wang X, Seubert JM, Graves JP, Bradbury JA, Zeldin DC, Lee HC.

J Physiol. 2006 Sep 1;575(Pt 2):627-44. Epub 2006 Jun 22.

4.

Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature.

Dhanasekaran A, Al-Saghir R, Lopez B, Zhu D, Gutterman DD, Jacobs ER, Medhora M.

Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H517-31. Epub 2006 Apr 14.

5.

Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis.

Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I, Busse R.

J Cell Sci. 2005 Dec 1;118(Pt 23):5489-98. Epub 2005 Nov 15.

6.

Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition.

Larsen BT, Miura H, Hatoum OA, Campbell WB, Hammock BD, Zeldin DC, Falck JR, Gutterman DD.

Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H491-9. Epub 2005 Oct 28.

7.

Cytochrome p450 2C inhibition reduces post-ischemic vascular dysfunction.

Hunter AL, Bai N, Laher I, Granville DJ.

Vascul Pharmacol. 2005 Oct;43(4):213-9. Epub 2005 Sep 8.

PMID:
16150654
8.

Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids.

Spiecker M, Liao JK.

Arch Biochem Biophys. 2005 Jan 15;433(2):413-20. Review.

PMID:
15581597
9.

Cytochrome P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel.

Gross ER, Nithipatikom K, Hsu AK, Peart JN, Falck JR, Campbell WB, Gross GJ.

J Mol Cell Cardiol. 2004 Dec;37(6):1245-9.

PMID:
15572055
10.

Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2.

Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, Node K, Börgel J, Mügge A, Lindpaintner K, Huesing A, Maisch B, Zeldin DC, Liao JK.

Circulation. 2004 Oct 12;110(15):2132-6. Epub 2004 Oct 4.

11.

Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2.

Xiao YF, Ke Q, Seubert JM, Bradbury JA, Graves J, Degraff LM, Falck JR, Krausz K, Gelboin HV, Morgan JP, Zeldin DC.

Mol Pharmacol. 2004 Dec;66(6):1607-16. Epub 2004 Sep 10.

12.

Nitric oxide insufficiency and atherothrombosis.

Voetsch B, Jin RC, Loscalzo J.

Histochem Cell Biol. 2004 Oct;122(4):353-67. Epub 2004 Aug 26. Review.

PMID:
15338226
13.

Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway.

Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, Gabel S, Gooch R, Foley J, Newman J, Mao L, Rockman HA, Hammock BD, Murphy E, Zeldin DC.

Circ Res. 2004 Sep 3;95(5):506-14. Epub 2004 Jul 15.

14.

Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues.

Enayetallah AE, French RA, Thibodeau MS, Grant DF.

J Histochem Cytochem. 2004 Apr;52(4):447-54.

PMID:
15033996
15.

Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors.

Granville DJ, Tashakkor B, Takeuchi C, Gustafsson AB, Huang C, Sayen MR, Wentworth P Jr, Yeager M, Gottlieb RA.

Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1321-6. Epub 2004 Jan 20.

16.

Cytochrome P450: major player in reperfusion injury.

Gottlieb RA.

Arch Biochem Biophys. 2003 Dec 15;420(2):262-7. Review.

PMID:
14654065
17.

Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction.

Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, De Faire U, Rane A.

Pharmacogenetics. 2003 Dec;13(12):715-20.

PMID:
14646690
18.

Regulation of endothelium-derived vasoactive autacoid production by hemodynamic forces.

Busse R, Fleming I.

Trends Pharmacol Sci. 2003 Jan;24(1):24-9. Review.

PMID:
12498727
19.

Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis.

Russo G, Leopold JA, Loscalzo J.

Vascul Pharmacol. 2002 May;38(5):259-69. Review.

PMID:
12487030
20.

Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension.

Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD.

Hypertension. 2002 Feb;39(2 Pt 2):690-4.

Supplemental Content

Support Center